Evidence map›Paper›PMID 31519301›Full record

Trial reportBrazilian journal of anesthesiology (Elsevier)

[Capsaicin topical cream (8%) for the treatment of myofascial pain syndrome].

Valéria Romero, Juliana Rodrigues Lara, Francisco Otero-Espinar, Manoel Henrique Salgado, Norma Sueli Pinheiro Modolo, Guilherme Antonio Moreira de Barros

Open access · diamondAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Brazilian journal of anesthesiology (Elsevier). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Capsaicin: Emerging Pharmacological and Therapeutic Insights.Current issues in molecular biology · 2024
    Review
  4. Burning measure for burning mouth syndrome: a systematic review.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2024
    Article
  5. Article
  6. The Utility ofInternational journal of environmental research and public health · 2022
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Valéria RomeroUniversidade Estadual Paulista (Unesp), Faculdade de Medicina, Departamento de Anestesiologia, Botucatu, SP, Brasil.
Juliana Rodrigues LaraUniversidade Estadual Paulista (Unesp), Faculdade de Medicina, Departamento de Anestesiologia, Botucatu, SP, Brasil.
Francisco Otero-EspinarUniversidade de Santiago de Compostela (USC), Faculdade de Farmácia, Departamento de Farmácia e Tecnologia Farmacêutica, Santiago de Compostela, Espanha.
Manoel Henrique SalgadoUniversidade Estadual Paulista (Unesp), Faculdade de Engenharia, Departamento de Engenharia Industrial, Bauru, SP, Brasil.
Norma Sueli Pinheiro ModoloUniversidade Estadual Paulista (Unesp), Faculdade de Medicina, Departamento de Anestesiologia, Botucatu, SP, Brasil.
Guilherme Antonio Moreira de BarrosUniversidade Estadual Paulista (Unesp), Faculdade de Medicina, Departamento de Anestesiologia, Botucatu, SP, Brasil. Electronic address: guilherme.am.barros@unesp.br.
Universidade Estadual Paulista (Unesp) · BRUniversidade de Santiago de Compostela · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMyofascial pain syndrome is a common cause of musculoskeletal pain. The objective of this study was to evaluate the potential analgesic action of 8% capsaicin cream for topical use in patients with myofascial pain syndrome.

methodsInitially, cream formulations of PLA (Placebo) and CPS (Capsaicin 8%) were developed and approved according to the current requirements of the health authority agency. The 40 participating patients were randomly assigned to the PLA and CPS groups in a double-blind fashion. Before the creams were topically administered, according to the allocation group, the local anesthetic was used for a period of 50minutes directly in the area of interest. The cream was applied to the area of the skin over the trigger point, represented by the area with pain at palpation, in an amount of 10g for 30minutes in a circular area of 24 mm diameter. Subsequently, the cream was removed and the skin tolerability parameters were evaluated. The pain was measured before and during the formulation application, as well as at 1 hour, 7 days, 30 days, and 60 days after the procedure, evaluated using a verbal numerical scale (from 0 to 10: with 0=no pain and 10=worst pain imaginable).

resultsNo patient in PLA Group had hyperemia or burning sensation at the site of application, while 85% of patients in CPS Group had hyperemia or burning sensation at 15minutes. These complaints disappeared 24hours after the cream was removed. The pain score in CPS Group decreased steadily up to the 60

conclusionApplication of the formulations did not cause macroscopic acute or chronic skin lesions in patients, and the 8% capsaicin formulation was beneficial and well tolerated.

Indexed as

AnalgesiaAdministration, TopicalCapsaicinDouble-Blind MethodFemaleHumansMaleMiddle AgedMyofascial Pain SyndromesOintmentsProspective StudiesCapsaicinOintmentsAdministração tópicaCapsaicinCapsaicinaMyofascial pain syndromePontos‐gatilhoSíndrome de dor miofascialTopical routeTrigger points

Identifiers

PMID31519301
PMCPMC9391859
OpenAlexW2972415393

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.